Osage University Partners-backed PMV has pushed its funding total to $236m as it further commercialises Princeton research stretching back to 1979.

Pfizer, Sanofi, Vertex Pharmaceuticals, Merck & Co and Amgen are in line for exits after the immunotherapy developer filed to go public.

Existing investor Hikma Ventures returned for a series B round that came amidst increased demand for Lemonaid's remote healthcare services.

Biocon's biosimilar subsidiary is valued at $3.5bn in the deal, which will involve Tata Capital acquiring a stake sized at under 1%.

Nestlé is the main backer of the consumer investment firm's latest fund, which has a $150m target for its final close.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

UCL Technology Fund 2 has achieved a first close on the way to its $131m target, with a cornerstone investment from UCL itself.

Axa Investment Managers was among the participants in a $13.9m round for Alydia, which is developing a system to treat postpartum haemorrhage.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

There are occasional silver linings even for the blackest clouds. One was as the Covid-19 disease broke out this year competition for deals became a little lighter.